Document is current
Any future updates will be listed below
-
Authors
Opoku, Nicholas O.
Doe, Felix
Agbogah, Mannel E.
Laryea, Rukaya
Gordor, Shelter K.
Donkor, Bismark S.
Anyomitse, Edwin
Kugali, Dickson
van Zutphen-van Geffen, Mariëlle
Navarro, Danielle J.
Rayner, Craig R.
Patel, Kashyap
Kuesel, Annette C.
Lowe, Melinda
Kinrade, Sally
-
Funding
Funding for this research was provided by:
Medicines Development for Global Health
- License Information
-
More Information
Article History
Received: 31 March 2025
Accepted: 10 June 2025
First Online: 24 July 2025
Declarations
:
: The protocol, information documents for potential participants and their parents/guardians, participant assent and parent/guardian consent forms as well as study conduct were approved by the Research Ethics Committee of the University of Health and Allied Sciences (UHAS), the Ethics Review Committee of the Ghana Health Service, the Ghana Food and Drugs Authority and the WHO Ethics Review Committee.
: Not applicable.
: ML and SK are staff of MDGH, Australia. WHO licensed all data on moxidectin at its disposal to MDGH to register moxidectin with a stringent regulatory authority and make moxidectin available to endemic countries which want to use moxidectin within their onchocerciasis elimination strategies. MDGH is the regulatory sponsor of moxidectin. ACK was on the staff of WHO responsible for all moxidectin-related activities in its department UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR). ACK retired from WHO in March 2023 and is continuing to work for TDR as a consultant.
